A construct can encode several intended immune targets. Each target still needs to be processed, displayed and recognized in the tested biological setting.
A primary multiepitope DNA-vaccine study found that flanking sequence changes altered processing efficiency and measured immunogenicity of encoded epitopes. That was evidence from the tested constructs, not a validated rule for every RNA cancer vaccine. The number of encoded epitopes is distinct from the number naturally displayed or recognized. Processing evidence, immune-response breadth and clinical outcome remain separate parts of a construct claim.
A computational study of spacer design for class-I-restricted string-of-beads polypeptides reported a fivefold increase in predicted epitope recovery and a 44 per cent reduction in predicted neo-epitope immunogenicity compared with designs without spacers (Schubert and Kohlbacher); these are predictions, not measured protection. Combining an N-terminal leader peptide with an MHC class I trafficking signal at the C terminus improved presentation of class I and class II epitopes in human and mouse dendritic cells and expanded antigen-specific CD8 and CD4 T cells in vitro and in mice (Kreiter and colleagues). In a first-in-human RNA poly-neo-epitope melanoma study all patients developed T-cell responses against multiple vaccine neo-epitopes (Sahin and colleagues; abstract only), and each patient's vaccine in the Rojas pancreatic cancer trial used two uridine mRNA strands, each encoding up to 10 neoepitopes. Mass spectrometry can identify recovered HLA-bound peptides. Caron and colleagues' 2015 review describes class I peptides predominantly 9 to 12 amino acids long and reports that about 10 per cent of acquired spectra could be confidently assigned at a 1 per cent false discovery rate in the workflows discussed. It also describes evidence that mass spectrometry underestimates the self-HLA peptide repertoire, so non-detection does not prove absence. Prediction is not presentation: of more than 1,300 amino acid changes in two mouse tumour models about 13 per cent were predicted to bind MHC class I and a small fraction of those were confirmed by mass spectrometry (Yadav and colleagues). Because a single amino acid after an epitope changed its immunogenicity in a multiepitope DNA vaccine (Livingston and colleagues, already linked), a changed spacer is a changed construct that needs renewed processing and display evidence, while earlier evidence is retained for the parts that did not change.
Shares Codon optimization, Messenger RNA construct anatomy, Immune measurements and product evidence.
Shares Immunodominance, Immune measurements and product evidence.
Shares Messenger RNA construct anatomy, Immune measurements and product evidence.
Shares Messenger RNA construct anatomy, Immune measurements and product evidence.
Shares Immunodominance, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/